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the cumulative rate at first but at the end a not statisti-
cally significant 8% higher incidence in the former
invited group. In other trials almost no excess
incidence was shown when the control group was
invited, which is to be interpreted as similar rates of
over-diagnosis in both groups.14
Exclusion of prevalent cases
We found a reduced, but remaining, excess incidence
after exclusion of prevalent cases (the first two screen-
ing rounds). This shows that the excess incidence is not
just related to prevalent cases in a population exposed
to screening. Two screening rounds correspond to four
years, and the average lead time has been estimated to
be two to four years depending on age.11 12 Most of the
prevalent cases in the invited group and their
corresponding controls should therefore have been
accounted for.
Factors influencing over-diagnosis
Attendance rates for screening decrease with age, as
shown in both the Malmö mammographic screening
trial and in the subsequent service screening
programme.15 16 On the other hand, women who had
been screened in the Malmö trial were more likely to
attend the service screening programme16 and
probably also to undergo mammography after screen-
ing had ended. Furthermore, mammography of
asymptomatic women outside the trial in the control
groups may lead to underestimation of over-diagnosis.
It is widely agreed that screening using mammog-
raphy can reduce mortality in breast cancer. The rate of
over-diagnosis is another issue to be considered in the
discussion on implications of breast cancer screening.
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Commentary: Over-diagnosis in breast cancer screening
Henrik Møller, Elizabeth Davies
The article by Zackrisson et al is an important
follow-up study of diagnosis of breast cancer in women
in the Malmö mammographic screening trial.1
In 2002 the International Agency for Research on
Cancer concluded that population mammographic
screening for women aged 50-69 years reduces the
mortality from breast cancer by about one third.2 But
screening can also lead to over-diagnosis and
over-treatment.3
Over-diagnosis arises from two distinct phenomena:
anticipation of diagnoses and excess diagnoses. Antici-
pation is the earlier diagnosis of cancers that would oth-
erwise have become symptomatic and presented later:
this phenomenon is both expected and desirable.
Excess diagnosis relates to cases detected through
screening that would otherwise never have presented.
A few may be false positive histological diagnoses, and
some will arise when women are diagnosed by screen-
ing but then die shortly afterwards from other
unrelated causes. Screening may also detect slow grow-
ing cancers that would not become symptomatic
within the normal life expectancy.
When a new cohort of women first attends
mammographic screening their incidence of breast
cancer increases substantially compared with that of an
unscreened cohort, owing to both anticipation and
excess cases. During subsequent screens the incidence
remains around 30% higher than before screening.4
What is already known on this topic
Rates of over-diagnosis in screening for breast
cancer have been estimated at 5% to 50%
Evidence from randomised controlled trials is
lacking
What this study adds
Over-diagnosis of breast cancer was 10% in
women randomised to screening at age 55-69
years compared with an unscreened control group
Calculations are based on direct observations of
follow-up 15 years after the end of a randomised
controlled trial
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Excess cases are more important here because
anticipation will relate only to new tumours that have
become detectable since the previous screen. Finally,
when screening ceases at around age 64-69, the
incidence returns to a lower than expected rate.
The most informative analysis in Zackrisson et al’s
study is the comparison of the cumulative incidence of
breast cancer in the screened and the non-screened
groups of women born between 1908 and 1922 and
randomised between 1976 and 1978.1 This is a mature
cohort with follow-up to 2001 when about 60% of the
women had died. The main finding is a 10% increase in
the lifetime occurrence of breast cancer (including
cancer in situ) in the screened group.
The study’s low statistical power precludes an exact
estimate of over-diagnosis (95% confidence limits
around the 10% estimate are 1% and 18%). Because
some women randomised to screening were not
screened and some women in the control group were,
the intention to screen analysis leads to somewhat con-
servative estimates of over-diagnosis and of the reduc-
tion in breast cancer mortality (around 17%).
To put these numbers into perspective, let us for
simplicity assume that they are both correct. In a popu-
lation where the lifetime risk of breast cancer is 8% and
the lifetime risk of dying from breast cancer from age
50 onwards is 2.5%, screening 250 women may prevent
about one death from breast cancer. Screening would,
however, also lead to the over-diagnosis of two cases.
The woman whose death from breast cancer is
prevented receives all the important benefit, whereas
the two over-diagnosed women pay part of the price by
becoming breast cancer patients and undergoing treat-
ment. We cannot predict, however, which three women
these will be.
The trouble is that although we can easily calculate
these or alternative numbers based on different sets of
data and assumptions, we cannot determine who the
three women are. Ideally we should try to identify
prognostic factors to distinguish the over-diagnosed
cases and reduce the aggressiveness of their treatment.
The first step towards this is to appreciate the reality of
over-diagnosis and its likely magnitude. Zackrisson et
al’s study should inspire similar estimations of
over-diagnosis in other populations, not only for breast
cancer but also for colorectal cancer, prostate cancer,
and other cancers, where organised screening or other
diagnostic tests are being introduced.
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Effectiveness of educational interventions in improving
detection and management of dementia in primary care:
cluster randomised controlled study
Murna Downs, Stephen Turner, Michelle Bryans, Jane Wilcock, John Keady, Enid Levin,
Ronan O’Carroll, Kate Howie, Steve Iliffe
Abstract
Objective To test the effectiveness of educational
interventions in improving detection rates and
management of dementia in primary care.
Design Unblinded, cluster randomised before and
after controlled study.
Setting General practices in the United Kingdom
(central Scotland and London) between 1999 and
2002.
Interventions Three educational interventions: an
electronic tutorial carried on a CD Rom; decision
support software built into the electronic medical
record; and practice based workshops.
Participants 36 practices participated in the study.
Eight practices were randomly assigned to the
electronic tutorial; eight to decision support software;
10 to practice based workshops; and 10 to control.
Electronic and manual searches yielded 450 valid and
usable medical records.
Main outcome measures Rates of detection of
dementia and the extent to which medical records
showed evidence of improved concordance with
guidelines regarding diagnosis and management of
dementia.
Results Decision support software (P = 0.01) and
practice based workshops (P = 0.01) both significantly
improved rates of detection compared with control.
There were no significant differences by intervention
in the measures of concordance with guidelines.
Conclusions Decision support systems and practice
based workshops are effective educational approaches
in improving detection rates in dementia.
Introduction
Inadequate detection of dementia in primary care and
poor management have been documented nationally
and internationally. People with dementia and their
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